Treatment of asthma in children with triamcinolone acetonide aerosol.
Triamcinolone acetonide aerosol, 100 microgram qid, was administered for 8 wk to 5 steroid-dependent asthmatic children and 10 who had not previously required continual corticosteroid treatment. Symptomatic control and pulmonary function improved in all 15 children despite discontinuation of oral corticosteroids in 3 of the steroid-dependent children. Determination of morning plasma cortisol concentrations disclosed no evidence of substantial adrenal suppression. Satisfactory symptomatic control has subsequently been maintained for 6 to 32 mo with doses of 100 microgram bid to 300 microgram qid without more extreme changes in plasma cortisol concentrations than were observed during the first 8 wk.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000336:Aerosols; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D010865:Pilot Projects; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*
D000305:Adrenal Cortex Hormones; D000336:Aerosols; D014222:Triamcinolone Acetonide; D006854:Hydrocortisone